info: HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
Changing Antiretroviral Therapy: Why, When, and How
Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naive HIV-infected patients. J Acquir Immune Defic Syndr 2001; 26:191-3 ... NEJM -- Cost-Effectiveness of Screening for HIV in the Era of Highly ...
Special Article from The New England Journal of Medicine -- Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy ... NEJM: Study on HAART, highly active antiretroviral therapy, to prevent ...
Study on HAART, highly active antiretroviral therapy, analyzes the effects of an intrapartum dose of nevirapine to prevent mother-to-child HIV transmission ... Response to highly active antiretroviral therapy strongly predicts ...
Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma AIDS 2003; July 2003 17(10):1521-1529 ... COULD HIGHLY ACTIVE ANTIRETROVIRAL THERAPY REDUCE HIV TRANSMISSION?
COULD HIGHLY ACTIVE ANTIRETROVIRAL THERAPY REDUCE HIV TRANSMISSION? by G.R. Scott, Consultant in Genito-urinary Medicine, Old Royal Infirmary, Edinburgh, Scotland ... http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030004
... Clinical Trial: Study of the HIV gp120/NefTat/AS02A Vaccine to Treat ...
Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART ... WHO | Antiretroviral therapy, Highly active
Antiretroviral therapy, Highly active This page provides links to descriptions of activities, reports, news and events, as well as contacts and cooperating partners in the various WHO programmes and ... FHI - Antiretroviral Therapy
This combination is called "highly active antiretroviral therapy" (HAART). Each class of ARV attacks the virus at a different stage of its replication, preventing it from replicating further or, at ... HIV Report March 2001 - When Should Highly Active Antiretroviral ...
When Should Highly Active Antiretroviral Therapy Be Initiated? By Timothy R. Sterling, M.D. Several factors contributed to the recent change in the guidelines for the initiation of ... Lancet, PLoS Publish Studies On Antiretroviral Therapy (Medical News Today)
"Mortality of HIV-1-Infected Patients in the First Year of Antiretroviral Therapy: Comparison Between Low-Income and High-Income Countries," Lancet: Matthias Egger of the Department of Social and Preventive Medicine at the University of Bern, Switzerland, and colleagues looked at the outcomes of the first year of highly active antiretroviral therapy in HIV-positive people in low- and high-income ... Free Antiretroviral Therapy Key To Success Of AIDS Treatment In Developing Countries (Medical News Today)
HIV-infected patients starting highly active antiretroviral therapy (HAART) in developing countries have increased mortality rates in the first months on therapy compared with those in developed countries, according to a paper in this week's issue of The Lancet. The authors state that early diagnosis and assessment of treatment eligibility, coupled with free provision of HAART, might reduce this ... Giving HIV patients 'drug holiday' fails in trial (Medical Post Online)
. The patients get a drug holiday.... HAART Is Cost Effective, Lowers Other Health Care Expenses, Study Says (Medical News Today)
"Distribution of Health Care Expenditures for HIV-Infected Patients," Clinical Infectious Diseases: Dr. Michael Saag and colleagues at the University of Alabama-Birmingham examined annual health care expenses for 635 HIV-positive people and found that highly active antiretroviral therapy is cost effective despite high costs -- about $10,000 to $15,000 annually -- to the patient click link for ... Computer Simulation Hints At New HIV Drug Target (Medical News Today)
For more than a year, researchers watched patiently as a few computer-simulated HIV protease molecules squirmed into more than 15,000 slightly different shapes. In real time, this contortion takes only a fraction of a second. In the end, however, this suspended animation paid off, as the simulations uncovered a potential new drug target to fight drug-resistant AIDS click link for more info.... Completely novel approach to fighting HIV infections (News-Medical-Net)
For more than a year, researchers watched patiently as a few computer-simulated HIV protease molecules squirmed into more than 15,000 slightly different shapes. In real time, this contortion takes only a fraction of a second.... US FDA traditional approval for Gilead's OD HIV medications Truvada, Viread (PharmaBiz)
The US FDA has granted traditional approval status Gilead Sciences' once-daily antiretroviral Viread (tenofovir disoproxil fumarate) and its fixed-dose product Truvada (emtricitabine and tenofovir disoproxil fumarate), which combines the company's two antiretrovirals Emtriva (emtricitabine) and Viread in a single daily tablet.... Update in Tuberculosis 2005 (RedNova)
By Yew, Wing Wai; Leung, Chi Chiu PATHOGENESIS AND IMMUNITY OF TUBERCULOSIS Among the reported genomic alterations of Mycobacterium tuberculosis, those involving the phospholipase C gene are of significant interest (1, 2).... HIV drug cocktail 'less effective' in poor countries (SciDev.net)
HIV/AIDS treatment programmes using drug cocktails that are standard in the industrialised world are proving less effective in developing countries, says a study published in The Lancet today (10 March).... Computer Simulation Hints at New HIV Drug Target (Newswise)
Using computer-simulated HIV protease molecules, HHMI scientists have identified a potential new drug target for drug-resistant HIV infection....
scented jar candle -
highly
active
antiretroviral
therapy
SITE MAP - HOME - All rights reserved. Tutti i diritti sono riservati.
11.27.44